• Prospective Real-World Data Shows Guselkumab Achieves Early Transmural Healing

    Prospective Real-World Data Shows Guselkumab Achieves Early Transmural Healing
    Originally published by our sister publication Gastroenterology & Endoscopy NewsBy Caroline HelwickNASHVILLE, Tenn.—In a real-world study of the interleukin-23p inhibitor guselkumab, a substantial number of patients with ulcerative colitis or Crohn’s disease achieved sonographic response and transmural healing as well as biochemical and clinical response by week 12, with further improvement observed over time.The study also demonstrated the utility of using intestinal ultrasound for earl

Follow @newsl_pharmacy on Twitter!